Selexipag: A New Treatment Agent for Pulmonary Arterial Hypertension
Journal Title: Meandros Medical and Dental Journal - Year 2019, Vol 20, Issue 1
Abstract
Pulmonary arterial hypertension (PAH) is a rare disease which is characterized by the progressive increase of pulmonary arterial pressure. PAH can lead to right cardiac insufficiency and death. Conventional and other treatment modalities that target the physiopathological and etiopathological causes of the disease are currently being used. Selexipag is an oral selective prostacyclin receptor agonist which was developed to overcome the pathophysiological mechanisms that play role in the PAH.
Authors and Affiliations
Onur Yazıcı, Hasan Güngör
Keywords
Related Articles
- EP ID EP551003
- DOI 10.4274/meandros.galenos.2017.20592
- Views 103
- Downloads 0
Effects of Intra-Articular Platelet-Rich Plasma Administration in Temporomandibular Joint Arthritis: An Experimental Study
Objective: Osteoarthritis is defined as a disease that begins with focal and progressive destruction in articular cartilage with biomechanical, biochemical, inflammatory and immunologic reactions and may cause pathologic...
Evaluation of The Patients Discharged from Emergency Department with Non-specific Chest Pain
Objective: The aim of this study is to evaluate 6-month fate of the patients who were discharged from the emergency department with the diagnosis of non-specific chest pain. Materials and Methods: Forty patients aged 18...
Place in Concomitant Use with Anti-EGFR Radiotherapy in Locally Advanced Head and Neck Cancer Treatment
.
Importance of Ethics in Surgical Practice
.
Repair of a Partial Anomalous Pulmonary Venous Connection After Mitral Valve Replacement: A Case Report
Partial anomalous pulmonary venous connection (PAPVC) is a rare congenital disorder with an incidence 0.5% of all congenital cardiac defects. Usually seen with congenital cardiac defects such as sinus venosus type intera...